Feeds › Clinical trial updates
Clinical trial updates
Drug and device trials that companies register on ClinicalTrials.gov: newly completed phase 3 studies, changes of status and the dates a study is due to finish.
About this data
- What it is
- ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
- Who files it
- The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
- How current
- We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
- Terms
- ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
- Worth knowing
- A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
- Not to be confused with
- FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.
All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.
Source and freshness · Information, not investment advice (disclaimer).
Studies updated per day, last 30 days
All industry-sponsored studies Sponsor matched to a public company
By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.
Latest clinical trial updates
Showing: ticker PII · All recent updates
Studies by the date their record was last updated.
| Updated | Study | SponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private. | PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages. | StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time). | Enrolled | Primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update. | Source |
|---|---|---|---|---|---|---|---|
| Oct 15, 2026 | Study of ADI-PEG 20, Venetoclax and Azacitidine in Acute Myeloid Leukemia NCT05001828 · Acute Myeloid Leukemia, Adult ADI-PEG 20 | PII Polaris Group | Phase 1 | Active, not recruiting | 38 | Jan 2027 | Registry ↗ |
| Jun 25, 2026 | Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma… NCT05712694 · Soft Tissue Sarcoma ADI PEG20, Placebo | PII Polaris Group | Phase 3 | Terminated | 218 | May 25, 2026 | Registry ↗ |
| Dec 18, 2025 | Study of ADI-PEG 20 Versus Placebo in Subjects With High Arginine Level and Unresectable Hepatocell… NCT05317819 · Hepatocellular Carcinoma, Advanced Hepatocellular Carcinoma ADI-PEG20, Placebo | PII Polaris Group | Phase 3 | Recruiting | 300 | Sep 2028 | Registry ↗ |
| Sep 23, 2025 | Study of ADI-PEG 20 Versus Placebo in Subjects With NASH NCT05842512 · Nonalcoholic Steatohepatitis (NASH) ADI-PEG20, Placebo | PII Polaris Group | Phase 2 | Recruiting | 60 | Dec 31, 2027 | Registry ↗ |
| Aug 26, 2025 | ADI-PEG 20 Plus Radiotherapy and Temozolomide in Subjects With Glioblastoma Multiforme NCT04587830 · Glioblastoma Multiforme (GBM) ADI-PEG 20, Temozolomide | PII Polaris Group | Phase 2 | Active, not recruiting | 100 | Feb 28, 2027 | Registry ↗ |
| Oct 4, 2023 | Ph 2/3 Study in Subjects With MPM to Assess ADI-PEG 20 With Pemetrexed and Cisplatin NCT02709512 · Mesothelioma ADI-PEG 20 plus Pem Platinum, Placebo plus Pem Platinum | PII Polaris Group | Phase 2/3 | Completed | 249 | Aug 15, 2022 | Registry ↗ |
| Apr 27, 2022 | Study ADI-PEG 20 Plus Pembrolizumab in Advanced Solid Cancers NCT03254732 · Advanced Solid Cancers ADI PEG20, Pembrolizumab | PII Polaris Group | Phase 1 | Terminated | 33 | May 7, 2019 | Registry ↗ |
| Apr 25, 2022 | Ph 1-2 Study ADI-PEG 20 Plus FOLFOX in Subjects With Advanced GI Malignancies Focusing on Hepatocel… NCT02102022 · Advanced Gastrointestinal (GI) Malignancies, Hepatocellular… ADI-PEG 20 plus modified FOLFOX6 | PII Polaris Group | Phase 1/2 | Terminated | 140 | Feb 2020 | Registry ↗ |
| Oct 1, 2020 | Ph 1B Trial With ADI-PEG 20 Plus Nab-Paclitaxel and Gemcitabine in Subjects With Pancreatic Cancer NCT02101580 · Advanced Pancreatic Cancer ADI-PEG 20 | PII Polaris Group | Phase 1 | Completed | 21 | May 5, 2017 | Registry ↗ |
| Oct 1, 2020 | PH 2 ADI-PEG 20 Acute Myeloid Leukemia NCT01910012 · Acute Myeloid Leukemia ADI-PEG 20 | PII Polaris Group | Phase 2 | Completed | 43 | Sep 12, 2016 | Registry ↗ |
| Sep 25, 2020 | Ph 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 With Pemetrexed and Cisp… NCT02029690 · Pleural Mesothelioma Malignant Advanced, Peritoneal Mesothe… ADI-PEG 20 | PII Polaris Group | Phase 1 | Terminated | 85 | Aug 15, 2018 | Registry ↗ |
| Mar 5, 2020 | Ph 1 Study of ADI-PEG 20 Plus Low Dose Cytarabine in Older Patients With AML NCT02875093 · Acute Myeloid Leukemia ADI-PEG 20, Cytarabine | PII Polaris Group | Phase 1 | Terminated | 23 | Jul 10, 2019 | Registry ↗ |
| Sep 6, 2019 | Ph 3 ADI-PEG 20 Versus Placebo in Subjects With Advanced Hepatocellular Carcinoma Who Have Failed P… NCT01287585 · Hepatocellular Carcinoma ADI-PEG 20 (arginine deiminase formulated with polyethylene… | PII Polaris Group | Phase 3 | Completed | 636 | Jul 2015 | Registry ↗ |
| Sep 18, 2018 | PH 2 ADI-PEG 20 Study in Non-Hodgkin's Lymphoma Subjects Who Have Failed Prior Systemic Therapy NCT01910025 · Non-Hodgkin's Lymphoma ADI-PEG 20 | PII Polaris Group | Phase 2 | Completed | 18 | Aug 31, 2016 | Registry ↗ |
| Sep 13, 2018 | Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Sm… NCT01497925 · Solid Tumors, Prostate Cancer ADI-PEG 20 | PII Polaris Group | Phase 1 | Completed | 43 | Mar 23, 2016 | Registry ↗ |
| Sep 4, 2018 | Ph 2 Trial of ADI PEG 20 Plus Concurrent Transarterial Chemoembolization (TACE) Vs TACE Alone in Pa… NCT02006030 · Unresectable Hepatocellular Carcinoma ADI-PEG 20, Transarterial chemoembolization | PII Polaris Group | Phase 2 | Completed | 30 | Jul 31, 2016 | Registry ↗ |
| Apr 14, 2016 | Ph 1 ADI-PEG 20 Plus Doxorubicin; Patients With HER2 Negative Metastatic Breast Cancer NCT01948843 · HER2 Negative Metastatic Breast Cancer ADI-PEG 20 | PII Polaris Group | Phase 1 | Completed | 15 | Apr 2016 | Registry ↗ |
| Mar 4, 2016 | Ph 1 Trial of ADI PEG 20 Plus Sorafenib to Treat Patients With Liver Cancer NCT02101593 · Hepatocellular Carcinoma ADI-PEG 20 | PII Polaris Group | Phase 1 | Completed | 8 | Feb 2016 | Registry ↗ |
| Feb 25, 2016 | Ph 1 Trial of ADI-PEG 20 Plus Cisplatin in Patients With Metastatic Melanoma NCT01665183 · Cutaneous Melanoma, Uveal Melanoma, Ovarian Carcinoma or Ot… ADI-PEG 20 | PII Polaris Group | Phase 1 | Completed | 8 | Feb 2016 | Registry ↗ |
19 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 5:51 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances